Compare AVLN & ROCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | ROCK |
|---|---|---|
| Founded | 2011 | 1972 |
| Country | United States | United States |
| Employees | N/A | 2221 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 1996 |
| Metric | AVLN | ROCK |
|---|---|---|
| Price | $27.52 | $39.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $62.25 | ★ $75.25 |
| AVG Volume (30 Days) | 192.8K | ★ 305.2K |
| Earning Date | 08-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,135,501,000.00 |
| Revenue This Year | N/A | $57.33 |
| Revenue Next Year | N/A | $6.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.90 | $33.56 |
| 52 Week High | $40.17 | $75.08 |
| Indicator | AVLN | ROCK |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 33.36 |
| Support Level | $25.86 | $38.09 |
| Resistance Level | $30.45 | $40.29 |
| Average True Range (ATR) | 2.25 | 1.66 |
| MACD | -0.56 | -0.38 |
| Stochastic Oscillator | 14.12 | 8.27 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.